Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain

Experimental Neurology

Volumn 224, Issue 1, 2010, Pages 207-218

  Schauwecker, Paula Elyse ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Hippocampus; Kainic acid; MK 801; Mouse strain; NBQX; Neuronal damage

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; DIZOCILPINE; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGE DISTRIBUTION; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EXCITOTOXICITY; HIPPOCAMPUS; HISTOPATHOLOGY; LOW DRUG DOSE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CELL COUNT; CELL DEATH; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FLUORESCENT ANTIBODY TECHNIQUE; KAINIC ACID; MICE; NEURONS; NEUROPROTECTIVE AGENTS; QUINOXALINES; SEIZURES; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY;

EID: 77953709019     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.013     Document Type: Article

References (79)

1. Auer R.N. Excitotoxic mechanisms, and age-related susceptibility to brain damage in ischemia, hypoglycemia and toxic mussel poisoning. Neurotoxicology 1991, 12:541-546.
2. 2+ signals and neuronal death in brain ischemia. Stroke 2007, 38:674-676.
3. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985, 14:375-403.
4. Ben-Ari Y., Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 2000, 23:580-587.
5. Berg M., Bruhn T., Johansen F.F., Diemer N.H. Kainic acid-induced seizures and brain damage in the rat: different effects of NMDA- and AMPA receptor antagonists. Pharmacol. Toxicol. 1993, 73:262-268.
6. Bertram E.H., Lothman E.W. NMDA receptor antagonists and limbic status epilepticus: a comparison with standard anticonvulsants. Epilepsy Res. 1990, 5:177-184.
7. Bessancon E., Guo S., Lok J., Tymianski M., Lo E.H. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci. 2008, 29:268-275.
8. Brandt C., Potschka H., Löscher W., Ebert U. N-methyl-d-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience 2003, 118:727-740.
9. Bullock R. Pathophysiologicla alterations in the central nervous system due to trauma. Schweiz Med. Wochenschr. 1993, 123:449-458.
10. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1:623-634.
11. Choi D.W. Excitotoxic cell death. J. Neurobiol. 1992, 23:1261-1276.
12. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 1990, 13:171-182.
13. Clark A.S., Magnusson K.R., Cotman C.W. In vitro autoradiography of hippocampal excitatory amino acid binding in aged Fischer 344 rats: relationship to performance on the Morris water maze. Behav. Neurosci. 1992, 106:324-335.
14. Clifford D.B., Olney J.W., Benz A.M., Fuller T.A., Zorumski C.F. Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990, 31:382-390.
15. Dalby N.O., Mody I. The process of epileptogenesis: a pathophysiological approach. Curr. Opin. Neurol. 2001, 14:187-192.
16. Daoudal G., Debanne D. Long-term plasticity of intrinsic excitability: learning rules and mechanisms. Learn. Mem. 2003, 10:456-465.
17. Fan M.M., Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
18. Fariello R.G., Golden G.T., Smith G.G., Reyes P.F. Potentiation of kainic acid epileptogenecity and sparing from neuronal damage by an NMDA receptor antagonist. Epilepsy Res. 1989, 3:206-213.
19. Farooqui A.A., Horrocks L.A. Excitotoxicity and neurological disorders: Involvement of membrane phospholipids. Int. Rev. Neurobiol. 1994, 36:267-323.
20. Ferreri G., Chimirri A., Russo E., Gitto R., Gareri P., De Sarro A., De Sarro G. Comparative anticonvulsant activity of N-acetyl-1-aryl-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives in rodents. Pharm. Biochem. Behav. 2004, 77:85-94.
21. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press, New York.
22. Frebel K., Wiese S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans. 2006, 34:1287-1290.
23. Hazell A.S. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 2007, 50:941-953.
24. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991, 252:851-853.
25. Hume R.I., Dingledine R., Heinemann S.F. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science 1991, 253:1028-1031.
26. Johnston M.V. Excitotoxicity in perinatal brain injury. Brain Pathol. 2005, 15:234-240.
27. Kesslak J.P., Yuan D., Neeper S., Cotman C.W. Vulnerability of the hippocampus to kainate excitotoxicity in the aged, mature and young adult rat. Neurosci. Lett. 1995, 188:117-120.
28. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 1999, 7:125-143.
29. Lallement G., Delamanche I.S., Pernot-Marino I., Baubichon D., Denoyer M., Carpentier P., Blanchet G. Neuroprotective activity of glutamate receptor antagonists against soman-induced hippocampal damage: quantification with an omega 3 site ligand. Brain Res. 1993, 618:227-237.
30. Lancelot E., Beal M.F. Glutamate toxicity in chronic neurodegenerative disease. Prog. Brain Res. 1998, 116:331-347.
31. Le D.A., Lipton S.A. Potential and current use of N-methyl-d-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 2001, 18:717-724.
32. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004, 1:101-110.
33. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 1997, 53:239-258.
34. Luer M.S., Rhoney D.H., Hughes M., Hatton J. New pharmacologic strategies for acute neuronal injury. Pharmacotherapy 1996, 16:830-848.
35. Magnusson K.R., Cotman C.W. Effects of aging on NMDA and MK-801 binding sites in mice. Brain Res. 1993, 604:334-337.
36. Mathern G.W., Kuhlman P.A., Mendoza D., Pretorius J.K. Human fascia dentata anatomy and hippocampal neuron densities differ depending on the epileptic syndrome and age at first seizure. J. Neuropathol. Exp. Neurol. 1997, 56:199-212.
37. Mattson M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 2003, 3:65-94.
38. McCord M.C., Lorenzana A., Bloom C.S., Chancer Z.A., Schauwecker P.E. Effect of age on kainate-induced seizure severity and cell death. Neuroscience 2008, 154:1143-1153.
39. Michaelis E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol. 1998, 54:369-415.
40. 2+ influx into striatal neurons by kainic acid. J. Pharmacol. Exp. Ther. 1989, 249:184-193.
41. Nadler J.V. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci. 1981, 29:2031-2042.
42. Nadler J.V., Perry B.W., Gentry C., Cotman C.W. Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells. Nature 1978, 271:676-677.
43. Nadler J.V., Perry B.W., Gentry C., Cotman C.W. Loss and reacquisition of hippocampal synapses after selective destruction of CA3-CA4 afferents with kainic acid. Brain Res. 1980, 191:387-403.
44. Nadler J.V., Perry B.W., Gentry C., Cotman C.W. Degeneration of hippocampal CA3 pyramidal cells induced by intraventricular kainic acid. J. Comp. Neurol. 1980, 192:333-359.
45. Nadler J.V., Evenson D.A. Use of excitatory amino acids to make axon-sparing lesions of the hypothalamus. Methods Enzymol. 1983, 103:393-400.
46. Nicholls D.G., Budd S.L. Neuronal excitotoxicity: the role of mitochondria. Biofactors 1998, 8:287-299.
47. Nicolle M.M., Bizon J.L., Gallagher M. In vitro autoradiography of ionotropic glutamate receptors in hippocampus and striatum of aged Long-Evans rats: relationship to spatial learning. Neuroscience 1996, 74:741-756.
48. Olney J.W. Kainic acid and other excitotoxins: a comparative analysis. Adv. Biochem. Pyschopharmacol. 1981, 27:375-384.
49. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an unpdate. Drug News Perspect. 1998, 11:523-569.
50. Pickard L., Noël J., Henley J.M., Collingridge G.L., Molnar E. Developmental changes in synaptic AMPA and NMDA receptor distribution and AMPA receptors. J. Neurosci. 2000, 20:7922-7931.
51. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
52. Raiteri M., Garrone B., Pittaluga A. N-methyl-d-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release. II. Evidence for functional cooperation and for coexistence on the same axon terminal. J. Pharmacol. Exp. Ther. 1992, 260:238-242.
53. Raza M., Deshpande L.S., Blair R.E., Carter D.S., Sombati S., DeLorenzo R.J. Aging is associated with elevated intracellular calcium levels and altered calcium homeostatic mechanisms in hippocampal neurons. Neurosci. Lett. 2007, 418:77-81.
54. Rice A.C., DeLorenzo R.J. NMDA receptor activation during status epilepticus is required for the development of epilepsy. Brain Res. 1998, 782:240-247.
55. Rubaj A., Zgodzinski W., Sieklucka-Dziuba M. The epileptogenic effect of seizures induced by hypoxia. The role of NMDA and AMPA/KA antagonists. Pharm. Biochem. Behav. 2003, 74:303-311.
56. Santos J.B., Schauwecker P.E. Protection provided by cyclosporin A against excitotoxic neuronal death is genotype dependent. Epilepsia 2003, 44:993-1000.
57. Sattler R., Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. J. Mol. Med. 2000, 78:3-13.
58. Schauwecker P.E. Seizure-induced neuronal death is associated with induction of c-Jun-N-terminal kinase and is dependent on genetic background. Brain Res. 2000, 884:116-128.
59. Schauwecker P.E. Complications associated with genetic background effects in models of experimental epilepsy. Prog. Brain Res. 2002, 135:139-148.
60. Schauwecker P.E. Modulation of cell death by mouse genotype: differential vulnerability to excitatory amino acid-induced lesions. Exp. Neurol. 2002, 178:219-235.
61. Schauwecker P.E., Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4103-4108.
62. Schauwecker P.E., Ramirez J.J., Steward O. Genetic dissection of the signals that induce synaptic reorganization. Exp. Neurol. 2000, 161:139-152.
63. Schauwecker P.E., Williams R.W., Santos J.B. Genetic control of sensitivity to hippocampal cell death induced by kainic acid: a quantitative trait loci analysis. J. Comp. Neurol. 2004, 477:96-107.
64. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honoré T. 2, 3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990, 247:571-574.
65. Sidman R.L., Angevine J.B., Taber Pierce E. Atlas of the mouse brain and spinal cord 1971, Harvard University Press, Cambridge.
66. Sloviter R.S. The functional organization of the hippocampal dentate gyrus and its relevance to the pathogenesis of temporal lobe epilepsy. Ann. Neurol. 1994, 35:640-654.
67. Smith S.E., Dürmüller N., Meldrum B.S. The non-N-methyl-d-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 1991, 201:179-183.
68. Sperk G. Kainic acid seizures in the rat. Prog. Neurobiol. 1994, 42:1-32.
69. Sperk G., Lassmann H., Baran H., Kish S.J., Seitelberger F., Hornykiewicz O. Neurochemical and histopathological changes. Neuroscience 1983, 10:1301-1315.
70. Sutula T., Koch J., Golarai G., Watanabe Y., McNamara J.O. NMDA receptor dependence of kindling and mossy fiber sprouting: evidence that the NMDA receptor regulates patterning of hippocampal circuits in the adult brain. J. Neurosci. 1996, 16:7398-7406.
71. Turski L., Jacobsen P., Honoré T., Stephens D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J. Pharmacol. Exp. Ther. 1992, 260:742-747.
72. Watanabe M., Fukaya M., Sakimura K., Manabe T., Mishina M., Inoue Y. Selective scarcity of NMDA receptor channel subunits in the stratum lucidum (mossy fibre-recipient layer) of the mouse hippocampal CA3 subfield. Eur. J. Neurosci. 2001, 10:478-487.
73. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.
74. Whetsell W.O. Current concepts of excitotoxicity. J. Neuropathol. Exp. Neurol. 1996, 55:1-13.
75. Wozniak D.F., Steward G.R., Miller J.P., Olney J.W. Age-related sensitivity to kainate neurotoxicity. Exp. Neurol. 1991, 114:250-253.
76. 2+)-permeable AMPA/kainate channels in hippocampal pyramidal neurons. J. Comp. Neurol. 1999, 409:250-260.
77. Yoshida M., Ohkoshi N., Tsuru N. Effects of acute treatment and long-term treatment with MK-801 against amygdaloid kindled seizures in rats. Epilepsy Res. 1997, 26:407-413.
78. Young A.B., Fagg G.E. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol. Sci. 1990, 11:126-133.
79. Zhang X., Cui S.S., Wallace A.E., Hannesson D.K., Schmued L.C., Saucier D.M., Honer W.G., Corcoran M.E. Relations between brain pathology and temporal lobe epilepsy. J. Neurosci. 2002, 22:6052-6061.